Related Experiment Video

Updated: Jun 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Targeting the epidermal growth factor receptor in non-small cell lung cancer

Martin B Steins1, Niels Reinmuth, Helge Bischoff

  • 1Clinic for Thoracic Diseases, University of Heidelberg, Germany. martin.steins@thoraxklinik-heidelberg.de

Onkologie
|December 3, 2010
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibition is a key strategy against cancer. This review highlights clinical data on EGFR tyrosine kinase inhibitors in non-small cell lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) signaling pathways are crucial in cancer development, including proliferation, migration, and survival.
  • EGFR plays a significant role in cancerogenesis and tumor progression.
  • Inhibition of EGFR is a validated therapeutic strategy in oncology.

Purpose of the Study:

  • To review clinical data on EGFR inhibition in cancer treatment.
  • To focus on the efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of clinical trial data.
  • Analysis of therapeutic strategies involving EGFR inhibition.
  • Emphasis on tyrosine kinase inhibitors.

Main Results:

  • Monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting EGFR have shown significant efficacy.
  • Clinical applications demonstrate the therapeutic potential of EGFR inhibition.
  • Specific focus on promising results in non-small cell lung cancer.

Conclusions:

  • EGFR inhibition is an effective approach for cancer therapy.
  • Tyrosine kinase inhibitors represent a major advancement in treating NSCLC.
  • Further clinical evaluation of EGFR-targeted therapies is warranted.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: